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Abstract
Background: Gender-related differences are seen in multiple aspects of both health and illness. Ischemic
heart disease (IHD) is a pathology in which diagnostic, treatment and prognostic differences are seen
between sexes, especially in the acute phase and in the hospital setting. The objective of the present study
is to analyze whether there are differences between men and women when examining associated
cardiovascular risk factors and secondary pharmacological prevention in the primary care setting.
Methods: Retrospective descriptive observational study from January to December of 2006, including
1907 patients diagnosed with ischemic heart disease in the city of Lleida, Spain. The clinical data were
obtained from computerized medical records and pharmaceutical records of medications dispensed in
pharmacies with official prescriptions. Data was analyzed using bivariate descriptive statistical analysis as
well as logistic regression.
Results: There were no gender-related differences in screening percentages for arterial hypertension,
diabetes, obesity, dyslipemia, and smoking. A greater percentage of women were hypertensive, obese and
diabetic compared to men. However, men showed a tendency to achieve control targets more easily than
women, with no statistically significant differences. In both sexes cardiovascular risk factors control was
inadequate, between 10 and 50%. For secondary pharmaceutical prevention, the percentages of
prescriptions were greater in men for anticoagulants, beta-blockers, lipid-lowering agents and angiotensin-
converting enzyme inhibitors/angiotensin II receptor blockers, with age group variations up to 10%. When
adjusting by age and specific diagnoses, differences were maintained for anticoagulants and lipid-lowering
agents.
Conclusion: Screening of cardiovascular risk factors was similar in men and women with IHD. Although
a greater percentage of women were hypertensive, diabetic or obese, their management of risk factors
tended to be worse than men. Overall, a poor control of cardiovascular risk factors was noted.
Taken as a whole, more men were prescribed secondary prevention drugs, with differences varying by age 
group and IHD diagnosis.
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Ischemic heart disease (IHD) is considered to be respon-
sible for approximately half of deaths in the Western
Hemisphere, in both men and women, even though glo-
bal prevalence of this disease is lower in women. In Spain
the incidence of IHD is among the lowest in the world.
Projects such as REGICOR (Girona Coronary Register) [1]
or WHO-MONICA-Catalunya [2] analyzed the standard-
ized annual incidence of acute myocardial infarction
(AMI), obtaining figures of 31–39 new cases per 100,000
women and 178–210 cases per 100,000 men.
The majority of patients with this pathology are over 65.
Above this age, prevalence increases rapidly among
women until it becomes the primary cause of death. In
fact, the incidence of infarct in women between 60–70
years old is the same as that of men ten years younger,
between 50–60 years old [3].
For a long time women have been invisible to the health
care system, to diagnosis processes and even to treatment.
This situation is known as Yentl syndrome. Women's
health problems have been reduced to social, cultural,
psychological and reproductive causes that have hidden
their physiology, their condition and their environment.
IHD is one of the diseases that most clearly shows biolog-
ical and gender inequalities: in diagnosis, treatment, pre-
vention and rehabilitation. Previous studies show that
there are important differences between men and women
in the clinical management of IHD, especially in patients
admitted with acute coronary pathologies: women arrive
an hour later to the hospital on the average, have more co
morbidity, progress to more severe conditions and have a
greater risk of adjusted mortality at 28 days [4]. With
regard to diagnostic tests, other research has shown that
women wait longer to be visited and to get an electrocar-
diogram, and are referred less often for coronary angiog-
raphies. Furthermore, revascularization and
pharmacological treatments at discharge are different,
with men being prescribed beta blockers and anticoagu-
lants more frequently [3].
Recently, a study done in the United Kingdom in a large
population diagnosed with angina showed that there are
also differences in primary care follow-up, in screening
and management of cardiovascular risk factors (CVRF),
and in the prescription of medication recommended for
secondary prevention [5].
In this context, the present study was proposed with the
following objective: to evaluate gender-related differences
in clinical follow-up of ischemic heart disease in a primary
care setting, both for detection and management of the
principal CVRF and the use of recommended medications
for secondary prevention.
Methods
This was a retrospective descriptive observational study
using data from a clinical registry. The study period was
from January to December of 2006. During this period,
the study scope (the city of Lleida, Spain) had a popula-
tion of 144,521 inhabitants, assigned to any of its basic
health areas (BHA). Those BHA belong to the Catalan
Institute of Health, the public institution which provides
primary and specialized health care services and prescrip-
tion drug coverage to 97% of the city population. All prac-
tices have been computerized since 2003 and share the
same information system, which made it possible to cre-
ate a comprehensive database from primary care records.
Analytic results, pharmaceutical prescription information
from specialists and hospital discharge diagnoses were
also available. All patients registered with a diagnosis of
ischemic heart disease (codes I20 – I25 of the ICD-10) in
the computerized primary care medical records by the 31st
of December 2006 were included in the study: this repre-
sents 1907 individuals, of whom 1266 were men and 641
women.
Being an observational retrospective study, no ethical
approval was considered necessary.
Variables
The data obtained from the clinical records were ano-
nymized. Variables studied were: sex, age, diagnosis of
hypertension, diagnosis of diabetes, diagnosis of obesity,
diagnosis of dyslipemia, diagnosis of smoking, arterial
pressure, basal blood glycemia, HbA1c, body mass index
(BMI), total and fractional cholesterol, optimal manage-
ment of systolic and diastolic blood pressure (SBP < 140
and DBP < 90), optimal glycosylated hemoglobin man-
agement (HbA1c < 7 mg), optimal management of BMI
(BMI < 25), optimal cholesterol management (LDL <
100) and prescribing of medications recommended for
secondary prevention: beta-blockers, antiplatelet/antico-
agulants, lipid-lowering agents and angiotensin convert-
ing enzyme inhibitors (ACE inhibitors)/angiotensin II
receptor blockers (ARB). Variables reflect the most recent
available data recorded during 2006. A CVRF was consid-
ered screened if the variable value was filled in during the
study period. Annual screening findings and previously
registered CVRF were gathered to produce CVRF year-
prevalence.
Data sources
Demographic and clinical data were obtained from the
primary care information system and the Catalan Health
Institute's computerized primary care medical records sys-
tem (SIAP/e-CAP), which registers administrative, clinicalPage 2 of 9
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Information relating to pharmaceutical prescriptions was
obtained from the pharmacy unit at the Catalan Health
Service, from databases of all prescribed medications pur-
chased by patients in pharmacies, irrespective of pre-
scriber.
Statistical Analysis
Once the two databases were linked, a descriptive study of
all the included qualitative variables was produced as fre-
quency tables and percentages. Quantitative variables
were described using means, medians and standard devi-
ations. The chi-squared test was used to determine statis-
tically significant differences between sexes in the
distribution of the various factors studied. In addition, age
and IHD diagnoses adjusted odds ratios (OR), with their
respective 95% confidence intervals (95% CI), were esti-
mated using generalized additive models (GAM) with
logit link [6]. P-values less than 0.01 were considered sig-
nificant.
Results
Characteristics of patients diagnosed with IHD in Lleida: 
sex, age and diagnoses
A total of 144,521 persons made up the population
assigned to the BHAs in the city of Lleida, of whom 1907
were registered in the SIAP/e-CAP system with a diagnosis
of IHD. This is equivalent to a global prevalence of 1.32%
(0.88% in women and 1.76% in men). Mean age of the
study population was 71.5 years (SD = 12). The mean age
for men was 69.2 (SD = 12), while mean age for women
was 76 (SD = 11).
Table 1 and Figure 1 show the prevalence of IHD grouped
by age and sex.
The most frequent diagnoses registered by sex were as fol-
lows: for men, chronic ischemic heart disease (55%),
acute myocardial infarction (25%), angina (16%) and
other ischemic diseases (4%). For women: chronic
ischemic heart disease (56%), angina (23%), acute myo-
Prevalence of IHD by age and sexFigur  1
Prevalence of IHD by age and sex.
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(4%).
Prevalence, screening and management of CVRF by gender
An evaluation was done as to whether patients with IHD
were screened for the principal modifiable CVRF and per-
centages by sex are presented in Table 2. Screening per-
centages for blood pressure, smoking and BMI were
similar between men and women, although they were
slightly higher in men. On the other hand, cholesterol and
basal glycemia screening percentages were slightly higher
in women. No observed differences were statistically sig-
nificant.
Annual screening findings and previously registered CVRF
produced CVRF prevalence by sex (Table 3). Women had
more hypertension (HTN), obesity and diabetes mellitus
(DM), while men were more likely to be smokers. Rates of
dyslipemia were similar in both groups.
The level of management of CVRF with respect to the cur-
rent established recommendations can be seen in Table 4,
differentiated by sex.
Management was assessed for the total number of patients
with each risk factor, except for BMI, which was calculated
for all the patients with IHD. When data about CVRF con-
trol was not registered, the patient was considered not
controlled for that item.
The percentage of men that achieved recommended man-
agement objectives is greater than that of women, for all
CVRF. These differences are not statistically significant.
Risk factor control was low for both sexes: 52% of hyper-
tensive patients with IHD had their blood pressure under
140/90 and this percentage dropped to 10.6% when con-
sidering patients whose body mass index was below 25.
Use of recommended medications for secondary 
prevention
Table 5 shows the percentage of patients who were dis-
pensed at least one prescription, for each of the four phar-
macological groups that have shown effectiveness in
secondary prevention, by sex. Dispensation percentages
were greater in men and all differences were statistically
significant except those for angiotensin-converting
enzyme inhibitors/angiotensin II receptor blockers.
Table 6 shows the unadjusted odds ratio for men with
respect to women. Differences were statistically significant
in all pharmacological groups, except for ACEinhibitors/
ARB.
Table 1: IHD prevalence rates by age and sex
MEN
(N = 1266)
WOMEN
(N = 641)
TOTAL
(N = 1907)
Age Groups N % N % %
≤ 44 37 0.08 5 0.01 0.05
45–54 97 1.02 23 0.25 0.64
55–64 262 4.03 57 0.83 2.38
65–74 355 8.00 131 2.32 4.82
75–84 405 11.57 273 5.19 7.74
> 84 110 10.77 152 6.60 7.88
Age (mean ± SD) 69.2 ± 12.0 76.0 ± 10.7 71.5 ± 12.0
Table 2: Percentage of patients screened for the following risk 
factors: HTN, dyslipemia, smoking, obesity, and diabetes
WOMEN
(n = 641)
MEN
(n = 1266)
TOTAL
(n = 1907)
Blood pressure 83.5 85.4 84.7
Cholesterol 71.8 68.8 69.8
Smoking 85.7 88.3 87.4
BMI 70.2 73.6 72.5
Glycemia 64.3 60.5 61.8
Table 3: Detected prevalence of modifiable cardiovascular risk 
factors
WOMEN
(n = 641)
MEN
(n = 1266)
TOTAL
(n = 1907)
% % N %
Hypertension * 70.8 57.1 1177 61.7
Dyslipemia 44.0 44.2 842 44.2
Smoker * 3.1 9 261 13.7
Obesity * 27.3 21.9 452 23.7
Diabetes Mellitus 36.8 32.4 646 33.9
* Distributions of risk factors with a p-value < 0.01 in the chi-squared 
test between men and women.Page 4 of 9
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different distribution in men and women and that pre-
scribing is related to both variables, odds ratios were recal-
culated adjusted for age and specific IHD diagnosis to
control the potential confounding effect of these varia-
bles. Statistically significant differences persisted for
antiplatelet/anticoagulant drugs and lipid-lowering
agents.
All differences vary by age group. In the 55–59 and 80–84
groups there are differences in pharmaceutical consump-
tion greater than 10%. Over age 80 there is a reduction of
consumption in both men and women (Figure 2).
Discussion
This study has some limitations that need to be clarified:
all clinical data were automatically and anonymously
obtained from electronic records, which are known to
have large accuracy and completeness variability, as
recently discussed by Majeed et al [7]; a systematic review
showed the highest rate of recording for prescriptions,
while morbidity was coded in 66% to 99% of consulta-
tions. Coronary heart disease was the most commonly
assessed and completely recorded disease (around 70%),
with a positive predictive value around 83–100%. In our
case, registration of cardiovascular diseases and control
variables has been continuously monitored and incentiv-
ized since 2006, with a set of clinical indicators to meas-
ure quality and outcomes. Nevertheless, measurement of
data quality in electronic records is limited at the
moment, because of a lack of reference standards for
reporting data quality in primary care. This should be
taken into account, as discussed later, when generalizing
the results.
All patients with IHD were included, so recently diag-
nosed patients may not have had time to reach targets, for
both men and women. This might represent a selection-
bias, but would not affect the gender differences, when
present.
As for results, they cannot be generalized to patients with
IHD but not covered by a public health system which pro-
vides comprehensive health care and drug coverage as
well as equality of access to sanitary services through a
gate keeper.
The global prevalence of IHD diagnosis in this study pop-
ulation was 1.32%. This percentage increased with age,
reaching 7% in subjects over 70. These figures are lower
than those found in other studies in our geographical area
(i.e. 5.5% in Barcelona, Baena et al) [8]. One cause for the
differences may be that our study used patients' electronic
medical records, registered by primary care clinicians dur-
ing patient consultations, with a possible bias toward
acute versus chronic presentations of disease, and towards
more symptomatic patients among both men and
women. Patients with angina only were not distinguished
from patients with angina and AMI or AMI without
angina, given that this was not the objective of the study.
All patients affected by any clinical form of IHD were
included, understanding that the secondary prevention
measures studied are indicated for all IHD presentations.
On the other hand, patients with IHD but without a regis-
tered diagnosis went undetected and were not included in
the study. Obviously, these results can not be generalized
to all patients with IHD, but only identified patients for
Table 4: Management of risk factors associated with ischemic heart disease as suggested in clinical practice guidelines, in percentage
TARGET WOMEN MEN TOTAL
SBP < 140 and DBP < 90, n = 1177 49.8 53.5 52.1
LDL < 100, n = 842 36.2 39.8 38.6
BMI < 25, n = 1907 9.7 11.1 10.6
HbA1c < 7, n = 646 33.1 35.1 34.4
The Chi-square test between men and women did not detect any statistical differences
Table 5: Percentage of consumption of medication containers by 
sex
Containers (> = 1) WOMEN
(n = 641)
MEN
(n = 1266)
TOTAL
(n = 1907)
Anticoagulants* 72.9 83.8 80.1
Beta-blockers* 43.8 51 48.6
ACE inhibitors/ARB 45.1 49.8 48.2
Lipid-lowering agents* 55.7 68 63.9
*p-value < 0.01 in the chi-squared test between men and women.Page 5 of 9
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clinicians.
The fact that the study population was entirely drawn
from recorded IHD diagnoses in one city means the group
analyzed was homogenous. Geographic characteristics
and the urban setting were the same. Available health care
services were similar because there is a single set of pri-
mary care, hospital, and specialist treatment available to
all residents, so differences can't be explained by these var-
iables.
Table 6: Non-adjusted and age/diagnosis adjusted odds ratio for pharmacological secondary prevention in men with respect to women
ORunadj C.I. 95% ORadj C.I. 95%
Any medication 1.63* (1.24–2.13) 1.43* (1.07–1.92)
Anticoagulants 1.93* (1.53–2.43) 1.81* (1.41–2.31)
Beta blockers 1.33* (1.10–1.62) 1.03 (0.84–1.27)
ACE inhibitors/ARB 1.20 (0.99–1.45) 1.15 (0.94–1.42)
Lipid-lowering agents 1.70* (1.39–2.05) 1.24* (1.01–1.53)
*p-value < 0,05 in the model adjusted for age and IHD specific diagnosis (chronic ischemic heart disease, acute myocardial infarction and angina)
Estimated age-adjusted OR using GAM link logit
Percentage (95% CI) of patients with any prescribed medication, by age and sexFigure 2
Percentage (95% CI) of patients with any prescribed medication, by age and sex.
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women, something seen in previous studies such as
PRESENAP – conducted in Spain in 2004 with a sample of
8817 patients with IHD, of whom 74% were men [9].
PRESENAP also observed that men presented this disease
at a younger age than women; our results show a mean
age for women seven years greater than that of men, fol-
lowing the pattern described in the medical literature.
Chronic ischemic heart disease is the most frequent diag-
nosis registered in both sexes. The most frequent second
diagnosis for men is acute myocardial infarct (23.3% vs.
17% in women), while the second most common diagno-
sis in women is angor pectoris (22.6% vs. 16% in men). The
Framingham Heart Study describes the initial presenta-
tion of IHD in women as angina and in men as AMI. This,
together with the greater proportion of normal coronari-
ographies in women, results in IHD being considered
more benign in women [10] and may have contributed
creating a gender stereotype with a negative influence on
management and prevention.
When analyzing screening, prevalence and management
of modifiable CVRF, the following points stand out.
Screening for some CVRFs was high: BP and smoking
behaviour were determined in more than 85% of patients,
while BMI was calculated in 72.5% of cases, and choles-
terol determined in 69.8%. On the other hand, only 62%
of patients had glycemia tests registered during the year of
the study. One recently published UK study by Crilly et al
[5], done in a primary care setting with 1162 patients with
angina, reported similar screening figures, greater than
85% for BP and smoking, and 72% for BMI. Screening
percentages were similar between men and women,
reflecting a growing sensitivity towards gender independ-
ent prevention. Men had slightly more frequent screening
for hypertension, BMI and smoking (between 2.1% and
3.4% greater), and women slightly more screening for gly-
cemia and cholesterol (between 3% and 3.8% greater).
These differences, however, were not statistically signifi-
cant.
The case of CVRF prevalence is different, with a greater
percentage of women than men being hypertensive
(70.8% vs. 57.1%, p < 0.01), obese (27.3% vs. 21.9%, p <
0.01) and diabetic (36.8% vs. 32.4%, p > 0.01). Compar-
ing our results with other studies conducted in our area in
patients of both sexes with IHD, such as the PRESENAP
study mentioned earlier (HTN 76.6%, DM 32.7%), or
with the Spanish data from EUROASPIRE II study
(Europe, primary care, 2000: HTN 42.6%, obesity 34.1%,
DM 39.2%) [11], our prevalence percentages are lower
than expected. These differences have been attributed to
diagnoses being obtained exclusively from coded regis-
tries in medical records generated by clinicians attending
patients and not the results of complementary tests
directly (BP, glycemia, BMI or cholesterol). The deficien-
cies in data entry in medical and hospital discharge
records have been discussed in the earlier EUROASPIRE II
study, in all participating European countries and at both
primary and secondary care levels, suggesting that hospi-
tal discharge reports should include CVRF histories, CVRF
measurements, prescribed treatments and management
objectives for patients. However, as expected, these num-
bers confirm the high prevalence of CVRF in the IHD pop-
ulation with respect to the general population in our area,
rates which are double that of the general population for
HTN or obesity, and triple for DM, as reported by Marin
et al in 2006 after five years of primary care follow-up of a
cohort of 6124 patients in Zaragoza [12].
Smoking, on the other hand, was much more common in
men than women (19% vs. 3.1%), coinciding with previ-
ously published figures [9]. It was the only CVRF which
was less frequent in the IHD population than in the gen-
eral population, reflecting, on one hand, the effect of
advanced age and, on the other, the tendency to stop
smoking when diagnosed with IHD. Nonetheless, one out
of five men continued to smoke.
The last factor studied, dyslipemia, affected both sexes
equally, at about 44%. Disparities with diagnostic criteria
used in other studies prevented comparison with our fig-
ures.
When analyzing the management of these CVRF in func-
tion of current recommendations, only 52.1% of IHD
patients had their BP below 140/90, with a slight predom-
inance of men (3.7% more men properly managed, p >
0.01). Other studies have reported highly variable rates
for this risk factor: 74.6% of the control group in the
PRESENAP study (Spain, primary care, 2004), 49.6% in
the l'EUROASPIRE II study (Europe, primary care, 2000)
or 38% in the NHANES III study (USA, primary care,
1994) [13].
The percentage of patients that maintained a LDL level
below 100 mg/dl was roughly 38.6%: the PRESENAP
study reported 26.3% and the NHANES III study reported
49%. The percentage of men with well-managed LDL was
greater than that of women by 3.6%, with no statistically
significant difference.
For diabetes, glycosylated hemoglobin was below seven in
34.4% of our cases, with 2% more men well managed
with respect to women (p > 0.01). This figure was 50.6%
in PRESENAP and 47% in NHANES III.Page 7 of 9
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10.6% of all patients maintained a BMI below 25, with
worse results in women, even though the difference was
minimal (1.4% p > 0.01).
In sum, although control of these CVRF was better in men,
the observed differences related to risk management were
not statistically significant.
Overall, CVRF management was poor in this group of
patients with IHD; the percentages would be even lower
when considering some of these CVRF simultaneously.
These poor results are not explained by lack of informa-
tion, because screening for CVRF was high.
The current recommendations for secondary prevention
of cardiovascular disease focus on the prescription of anti-
coagulants, beta blockers, ACE inhibitors/ARB and lipid-
lowering agents. The percentage of prescriptions in the
study population were greater than those reported in
other studies for beta-blockers and lipid-lowering agents,
and less for anticoagulants: the cited work of Crilly et al
refers to 35% for prescriptions of beta-blockers and 55%
for statins compared to 48.6% and 64%, respectively, in
our study population. Antiplatelet/anticoagulant drugs
were prescribed in 84% of their cases while in our study
the figure was 80% [5].
Men in our study population had a greater probability of
receiving medications from any of the four pharmaceuti-
cal groups than women, and this relationship tended to
persist when adjusting for age. Studying the four types of
medications individually by age groups and by IHD spe-
cific diagnosis, there continued to be differences, which
were significant for anticoagulant/antiplatelet drugs and
lipid-lowering agents. There is no evidence to suggest that
secondary prevention is more effective in men than in
women, so there should not be any gender-related differ-
ences in the results. Our findings are consistent with those
described in other studies that analyzed gender-related
inequalities in health ([2,4] and [14]) and suggest that
clinical diagnosis (angor pectoris, AMI, chronic IHD) may
be related to these differences, taking into account that
women tend to present more frequently with angor pectoris
than men, and this may condition the quantity and qual-
ity of treatment. It is possible that men receive more anti-
coagulant medication because they present more
frequently with AMI than with angina, and more lipid-
lowering agents because of the perception that IHD is
more serious in them. On the other hand, these differ-
ences disappear for ACE inhibitors/ARB and beta-blockers
when adjusted for diagnosis, probably because hyperten-
sion is more common in women and these drugs are
widely used for its treatment.
Other gender-related variables were not available and not
examined, such as co morbidity, which may influence the
decision of whether to prescribe a given medication to a
given patient, acting as confounding factors. All these
hypotheses need to be examined in studies specifically
designed to address them.
Conclusion
There were no important observed differences between
men and women with IHD related to CVRF screening. On
the whole, recorded screening activity can be considered
elevated for HTN and smoking, and needing improve-
ment with regard to obesity, dyslipemia and diabetes.
The prevalence of these factors is consistent with the
expected values for this population, with HTN, DM and
obesity being the most frequent among women.
Adequate management of CVRF tended to be slightly
worse in women, with no statistically significant differ-
ences. Overall, it is important to note the poor control of
CVRF in patients with established heart disease, both men
and women. Primary care physicians as well as hospital
specialists should be aware of these findings and consider
the reasons for this deficiency.
Gender-related inequalities were seen in medications pro-
vided for secondary IHD prevention. Men had a greater
probability of receiving any of the recommended medica-
tions and this result persisted across all age groups, a dif-
ference which is not justified by the currently available
evidence, since the demonstrated beneficial effects of
these treatments on the evolution of disease are the same
regardless of the sex of the patient.
As a final conclusion, our findings confirm that gender
differences are still found in the management of patients
with IHD: attention has to focus on women in order to
detect avoidable gender-bias, and consequently, worse
health results.
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